Back

Prognostic utility of left ventricular global longitudinal strain in patients with systemic amyloidosis.

27 August 2022 (15:30 - 15:40)
Organised by:
Congress Presentation Part of: Clinical implications of new methods to assess cardiac function Deformation Imaging ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Kirtipal Bhatia

Mount Sinai Morningside, New York (United States of America)

5 More presentations in this session

Presentation thumbnail
Right ventricular function and outcome in patients undergoing transcatheter mitral valve repair
Doctor M. Koschutnik (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Left atrial strain at CMR is a strong independent prognostic predictor in DCM, superior to LV-GLS, LVEF and LAVI, and incremental to LGE
Miss A. Raafs (Eindhoven, NL)
Abstract Slides Video
Presentation thumbnail
Regional strain score as prognostic marker of cardiovascular events. from the multi-ethnic study of atherosclerosis (MESA)
Doctor T. Pezel (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Cardiovascular structure and function assessed by MRI in healthy South Asians compared to White Europeans: a UK Biobank study
Mrs K. Parke (Leicester, GB)
Abstract Slides Video
Presentation thumbnail
Left ventricular kinetic energy across heart failure subgroups and subclinical diastolic dysfunction
Doctor A. Nelsson (Lund, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical implications of new methods to assess cardiac function

The Event

Event poster

ESC Congress 2022

27 August 2022 15:30 CET
You may be interested in
thumbnail
Congress Presentation
Echocardiography at the core of cardiac amyloidosis
thumbnail
Congress Presentation
Exploring ATTR cardiomyopathy: the journey to improved outcomes
thumbnail
Congress Presentation
Global longitudinal strain for prognostic staging in wild-type transthyretin cardiac amyloidosis, including under tafamidis treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources